Rong F. Sheng

State Key Laboratory Of Advanced Drug Delivery And Release Systems
Hangzhou, 310058, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Evaluation of 18F-FPPA as a Positron Emission Tomography Radioligand for Imaging CSF1R in LPS-Induced Rat Model of Neuroinflammation.

Evaluation of 18F-FPPA as a Positron Emission Tomography Radioligand for Imaging CSF1R in LPS-Induced Rat Model of Neuroinflammation.

Journal: Molecular pharmaceutics

Published: February 28, 2026

Discovery of Tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione Derivatives as Novel RIPK1 Inhibitors via Pharmacophore-Based Virtual Screening.

Discovery of Tetrahydropyrrolo[3,4-c]pyrrole-1,3-dione Derivatives as Novel RIPK1 Inhibitors via Pharmacophore-Based Virtual Screening.

Journal: Drug development research

Published: September 30, 2025

Discovery of RP-37 analogues as potent, selective irreversible inhibitors targeting DNA polymerase theta (POLθ).

Discovery of RP-37 analogues as potent, selective irreversible inhibitors targeting DNA polymerase theta (POLθ).

Journal: RSC medicinal chemistry

Published: September 17, 2025

HitScreen: A Sequence-Based Drug Virtual Screening Approach Using Data Augmentation and Protein Language Models.

HitScreen: A Sequence-Based Drug Virtual Screening Approach Using Data Augmentation and Protein Language Models.

Journal: Journal of chemical information and modeling

Published: September 16, 2025

Discovery of N-(thiazol-2-yl) Furanamide Derivatives as Potent Orally Efficacious AR Antagonists with Low BBB Permeability.

Discovery of N-(thiazol-2-yl) Furanamide Derivatives as Potent Orally Efficacious AR Antagonists with Low BBB Permeability.

Journal: Journal of medicinal chemistry

Published: September 10, 2025

Discovery of 1-(arylacetyl)-2-phenyl-pyrrolidine Derivatives as Novel POLθ-pol Inhibitors via Structure-Based Virtual Screening and Fragment Fusion.

Discovery of 1-(arylacetyl)-2-phenyl-pyrrolidine Derivatives as Novel POLθ-pol Inhibitors via Structure-Based Virtual Screening and Fragment Fusion.

Journal: Drug development research

Published: September 10, 2025

Unraveling the Efficacy of AR Antagonists Bearing N-(4-(Benzyloxy)phenyl)piperidine-1-sulfonamide Scaffold in Prostate Cancer Therapy by Targeting LBP Mutations.

Unraveling the Efficacy of AR Antagonists Bearing N-(4-(Benzyloxy)phenyl)piperidine-1-sulfonamide Scaffold in Prostate Cancer Therapy by Targeting LBP Mutations.

Journal: Journal of medicinal chemistry

Published: June 03, 2025

Corrigendum to "Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists" [Eur. J. Med. Chem. 291 (2025) 117566].

Corrigendum to "Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists" [Eur. J. Med. Chem. 291 (2025) 117566].

Journal: European journal of medicinal chemistry

Published: May 04, 2025

Virtual Screening of HBV Capsid Assembly Modulators with the Combination of Pharmacophore Modeling and Hydrogen Bond Constraints.

Virtual Screening of HBV Capsid Assembly Modulators with the Combination of Pharmacophore Modeling and Hydrogen Bond Constraints.

Journal: Medicinal chemistry (Shariqah (United Arab Emirates))

Published: April 23, 2025

Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists.

Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists.

Journal: Journal of medicinal chemistry

Published: January 23, 2025

Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists.

Discovery of novel tetrahydroquinoline derivatives as potent, selective, and orally Available AR antagonists.

Journal: European journal of medicinal chemistry

Published: January 20, 2025

Design, Synthesis, and Biological Evaluation of Novel 2-Heteroaryl-oxazolidine-4-one Derivatives as Novel HBV Capsid Assembly Modulators.

Design, Synthesis, and Biological Evaluation of Novel 2-Heteroaryl-oxazolidine-4-one Derivatives as Novel HBV Capsid Assembly Modulators.

Journal: Biological & pharmaceutical bulletin

Published: December 08, 2024

Showing 1-12 of 76

Last Updated: 09/26/2026